Trial Profile
Phase 2 Study Assessing Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone in Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 20 Sep 2022 According to ClinicalTrials.gov record, protocol has been amended as change in timeframe for primary endpoint from 16 weeks to 22 weeks.
- 25 Oct 2021 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 1 Mar 2022 to 1 Apr 2022.